This Article Full Text (PDF) All Versions of this Article: 1352458509345906v1 15/11/1295    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Young, J. Articles by Taylor, B. PubMed PubMed Citation Articles by Young, J. Articles by Taylor, B. Social Bookmarking                         What's this?

Clinically isolated acute transverse myelitis: prognostic features and incidence

Department of Neurology, Christchurch Public Hospital, Christchurch, New Zealand

Stephen Quinn

Menzies Research Institute, University of Tasmania, Hobart, Australia

Mike Hurrell

Department of Radiology, Christchurch Public Hospital, Christchurch, New Zealand

Bruce Taylor

Menzies Research Institute, University of Tasmania, Hobart, Australia, bruce.taylor{at}utas.edu.au

Demyelinating acute transverse myelitis may be the first presentation of multiple sclerosis or remain a clinically isolated syndrome. North Canterbury, New Zealand provides a well circumscribed population to study acute transverse myelitis. Objective: to identify prognostic features, clinical outcomes and incidence of ATM in North Canterbury, New Zealand. All patients with acute transverse myelitis as a first neurological presentation diagnosed from January 2001 to December 2005 at a single institution providing all neurological care for North Canterbury were assessed for clinical data, MRI findings, cerebrospinal fluid results and clinical outcomes. CHAMPS, Barkhof/Tintore and Swanton criteria were applied to brain MRI. Sixty-one patients were identified with a mean duration of follow-up of 30 ± 17 months. Fifty percent of patients with ATM with brain lesions by CHAMPS criteria converted to clinically definite multiple sclerosis. No patients with idiopathic acute transverse myelitis converted to clinically definite multiple sclerosis. There was a strong association with conversion to clinically definite multiple sclerosis and abnormal brain MRI by CHAMPS criteria (hazard ratio, 5.63; 1.83—17.3), Barkhof/Tintore criteria (hazard ratio, 6.43; 2.31—17.9) and Swanton criteria (hazard ratio, 4.53; 1.67—12.3). The age standardized annual incidence of acute transverse myelitis was 24.6 (18.2—31.1) per million, of definite and possible idiopathic acute transverse myelitis was 6.2 (2.9—9.6) per million, and of acute transverse myelitis with brain lesions was 4.7 (1.9—7.6) per million. Patients with idiopathic acute transverse myelitis are at low risk for conversion to clinically definite multiple sclerosis. Abnormal brain MRI by CHAMPS criteria is a sensitive predictor of conversion to clinically definite multiple sclerosis. The annual incidence of acute transverse multiple sclerosis in North Canterbury, New Zealand is significantly higher than previously reported.

Key Words: acute transverse myelitis • multiple sclerosis • incidence • MRI • prognostic factors

This version was published on November 1, 2009

Multiple Sclerosis, Vol. 15, No. 11, 1295-1302 (2009)
DOI: 10.1177/1352458509345906


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?